Company intelligence / Profile preview

Network Immunology

Vancouver, British Columbia, Canadanetworkimmunology.com ↗

Ownership: Private
Employees: ~6
Development stage: Other

Overview

Network Immunology’s AbstimX™ platform has demonstrated efficacy in preclinical models for resetting and rebalancing the immune system, showing promise for long-term treatment of allergies, autoimmune conditions, and chronic inflammatory diseases. Veterinary programs are expected to reach the market first, followed by human indications. No published clinical trial results yet; all data referenced is preclinical or projected pipeline timelines

Therapeutic areas: ImmunologyGastroenterology
Modalities: BiologicImmunotherapy (platform-based)
Industry: Biotech

Partnerships

In licensing/distribution discussions with two large animal health product companies

Beyond the preview

Go deeper on Network Immunology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Network Immunology.

Explore the full profile